|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Both primary breast lymphoma and lymphoma with concurrent BCL2-IGH and MYC translocations are rare and are primarily seen in adult patients.
|
21491965 |
2012 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Many of the cases in this DLBCL/BL category contain a translocation of MYC as well as BCL2, so-called "double-hit lymphomas" which have a very aggressive clinical behavior.
|
22035756 |
2011 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
An intriguing subset is formed by the so-called double- hit (DH) lymphomas that are defined by a chromosomal breakpoint affecting the MYC/8q24 locus in combination with another recurrent breakpoint, mainly a t(14;18)(q32;q21) involving BCL2.
|
21119107 |
2011 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
EZH2 mutations were frequently associated with the presence of BCL2 rearrangement (BCL2-R) in both the FL (28% of BCL-R cases versus 0% of BCL2-WT cases, p<0.05) and GCB-DLBCL groups (33% of BCL2-R cases versus 4% of BCL2-WT cases, p<0.04), and across all lymphoma types excluding BL (27% of BCL2-R cases versus 3% of BCL2-WT cases, p<0.003).
|
22194861 |
2011 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
4E-BP1 expression was also demonstrable in all 4 lymph nodes with in situ or partial involvement by follicular lymphoma and in all 12 cases of BCL2-negative lymphoma.
|
21366462 |
2011 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
We studied the efficacy of 2 germinal center B-cell markers, HGAL and LMO2, in the separation of lymphomas derived from small B cells, particularly follicular lymphoma (FL) and marginal zone lymphoma occurring in nodal, extranodal, splenic, and bone marrow sites using immunohistochemical analysis for CD10, BCL6, BCL2, HGAL, and LMO2.
|
21502424 |
2011 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).
|
21560251 |
2011 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Bcl2 promoter shift from P1 (the 5' promoter) to P2 (the 3' promoter) was observed in B cells from Igh-3'E-bcl2 mice, similar to human t(14;18) lymphomas.
|
21606958 |
2011 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A case-control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression.
|
20232134 |
2010 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The differential distribution of the plasma cells, specifically in relation to the presence or absence of an isolated BCL2 rearrangement suggests that the latter cases may be distinctive, sharing some features with marginal zone lymphomas.
|
19838161 |
2010 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Positivity rates of C-myc, Bcl-2 and Bax expression were 100%, 95.2%, and 90.5%, respectively, in the 21 cases of EBV-associated lymphomas.
|
20845810 |
2010 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
B-cell overexpression of Bcl-2 cooperates with p21 deficiency for the induction of autoimmunity and lymphomas.
|
20691570 |
2010 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
BI79D10 also effectively induces apoptosis of the RS11846 human lymphoma cell line in a dose-dependent manner and shows little cytotoxicity against bax-/-bak-/- mouse embryonic fibroblast cells, in which antiapoptotic Bcl-2 family proteins lack a cytoprotective phenotype, implying that BI79D10 has little off-target effects.
|
19372563 |
2009 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin.
|
19363496 |
2009 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Here we discuss the function of BCL-2 family proteins in germinal centre reactions, their deregulation in malignancies of germinal centre origin, and the potential for targeting BCL-2-related proteins therapeutically in lymphomas.
|
19922301 |
2009 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1).
|
19597184 |
2009 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Lymphomas with BCL6- and BCL2-translocations were very similar to t(14;18)-positive lymphomas without BCL6-translocations.
|
20032416 |
2009 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
It is highly debated whether cases of follicular lymphoma without BCL-2 gene rearrangement and expression represent a separate lymphoma entity with distinct biological characteristics, different from the BCL-2-positive cases.
|
18945749 |
2008 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our data support the notion that among gastrointestinal MALT lymphomas, t(14;18)-(IgH;Bcl-2) translocation clusters in HCV-positive patients sustaining the role of HCV infection in the lymphoma development.
|
18538438 |
2008 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
LHGDN |
CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34- cells in childhood AML.
|
18228020 |
2008 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Our data support the notion that among gastrointestinal MALT lymphomas, t(14;18)-(IgH;Bcl-2) translocation clusters in HCV-positive patients sustaining the role of HCV infection in the lymphoma development.
|
18538438 |
2008 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This study reveals a new aspect of the regulatory role of the IgH 3' enhancers on bcl-2 transcription in t(14;18) lymphomas.
|
18695675 |
2008 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
To examine a IgH/bcl-2 hybrid gene and VH gene to investigate the nature of the lymphoma cells and how they differ from nodal follicular lymphomas and MALT lymphomas.
|
17601964 |
2008 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Molecular mechanisms responsible for lymphoma resistance to apoptosis often involve the bcl-2 pathway.
|
18375822 |
2008 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Whereas a single or limited exposure of lymphoma cells to rituximab may lead to a favorable ratio of proapoptotic to antiapoptotic Bcl-2 family proteins, repeated exposure to rituximab is associated with a therapy-resistant phenotype via modulation of Bax and Bak expression.
|
18316580 |
2008 |